201 related articles for article (PubMed ID: 29940880)
41. Access to essential medicines to treat chronic respiratory disease in low-income countries.
Bissell K; Perrin C; Beran D
Int J Tuberc Lung Dis; 2016 Jun; 20(6):717-28. PubMed ID: 27155173
[TBL] [Abstract][Full Text] [Related]
42. WHO essential medicines policies and use in developing and transitional countries: an analysis of reported policy implementation and medicines use surveys.
Holloway KA; Henry D
PLoS Med; 2014 Sep; 11(9):e1001724. PubMed ID: 25226527
[TBL] [Abstract][Full Text] [Related]
43. Challenges in managing infections among pediatric cancer patients: Suboptimal national essential medicines lists for low and middle income countries.
Kirby J; Ojha RP; Johnson KM; Bittner EC; Caniza MA
Pediatr Blood Cancer; 2015 Feb; 62(2):204-207. PubMed ID: 25307693
[TBL] [Abstract][Full Text] [Related]
44. Mapping the selection, availability, price and affordability of essential medicines for mental health conditions at a global level.
Todesco B; Ostuzzi G; Barbui C
Epidemiol Psychiatr Sci; 2022 Apr; 31():e22. PubMed ID: 35438063
[TBL] [Abstract][Full Text] [Related]
45. The evolution of Reference Drug Lists and Clinical Practice Guidelines in the public health system of a middle-income country.
Rico-Alba I; Figueras A
Br J Clin Pharmacol; 2014 Aug; 78(2):410-21. PubMed ID: 25099259
[TBL] [Abstract][Full Text] [Related]
46. A comparison of national essential medicines lists in the Americas.
Steiner L; Maraj D; Woods H; Jarvis J; Yaphe H; Adekoya I; Bali A; Persaud N
Rev Panam Salud Publica; 2020; 44():e5. PubMed ID: 31998375
[TBL] [Abstract][Full Text] [Related]
47. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
[TBL] [Abstract][Full Text] [Related]
48. Outpatient cardiovascular diseases and diabetes medicines dispensing in the population with government health insurance in Syria between 2018 and 2019: a retrospective analysis.
Aljadeeah S; Nagel E; Wirtz VJ
BMC Health Serv Res; 2021 Oct; 21(1):1088. PubMed ID: 34645430
[TBL] [Abstract][Full Text] [Related]
49. Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries.
Uthman OA; Hartley L; Rees K; Taylor F; Ebrahim S; Clarke A
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011163. PubMed ID: 26272648
[TBL] [Abstract][Full Text] [Related]
50. Access to medicines through health systems in low- and middle-income countries.
Ozawa S; Shankar R; Leopold C; Orubu S
Health Policy Plan; 2019 Dec; 34(Supplement_3):iii1-iii3. PubMed ID: 31816069
[TBL] [Abstract][Full Text] [Related]
51. High medicine prices and poor affordability.
Suh GH
Curr Opin Psychiatry; 2011 Jul; 24(4):341-5. PubMed ID: 21532479
[TBL] [Abstract][Full Text] [Related]
52. Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study.
Taglione MS; Persaud N
BMJ Open; 2021 Aug; 11(8):e045262. PubMed ID: 34380717
[TBL] [Abstract][Full Text] [Related]
53. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.
Chow CK; Ramasundarahettige C; Hu W; AlHabib KF; Avezum A; Cheng X; Chifamba J; Dagenais G; Dans A; Egbujie BA; Gupta R; Iqbal R; Ismail N; Keskinler MV; Khatib R; Kruger L; Kumar R; Lanas F; Lear S; Lopez-Jaramillo P; McKee M; Mohammadifard N; Mohan V; Mony P; Orlandini A; Rosengren A; Vijayakumar K; Wei L; Yeates K; Yusoff K; Yusuf R; Yusufali A; Zatonska K; Zhou Y; Islam S; Corsi D; Rangarajan S; Teo K; Gerstein HC; Yusuf S;
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):798-808. PubMed ID: 30170949
[TBL] [Abstract][Full Text] [Related]
54. Shortages and price variability of essential cytotoxic medicines for treating children with cancers.
Martei YM; Iwamoto K; Barr RD; Wiernkowski JT; Robertson J
BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33173011
[TBL] [Abstract][Full Text] [Related]
55. Essential medicines for cardiovascular diseases in India: Rapid appraisal of policies and processes at the subnational level.
Garg A; Murphy A; Krishna A; Sahoo SK; Huffman MD; Kishore SP; Shivashankar R
Natl Med J India; 2022; 35(6):357-363. PubMed ID: 37167513
[TBL] [Abstract][Full Text] [Related]
56. Essential medicines are more available than other medicines around the globe.
Bazargani YT; Ewen M; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
PLoS One; 2014; 9(2):e87576. PubMed ID: 24533058
[TBL] [Abstract][Full Text] [Related]
57. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
Sanz G; Fuster V
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):101-10. PubMed ID: 19104519
[TBL] [Abstract][Full Text] [Related]
58. Financial Burden and Impoverishment Due to Cardiovascular Medications in Low and Middle Income Countries: An Illustration from India.
Pandey KR; Meltzer DO
PLoS One; 2016; 11(5):e0155293. PubMed ID: 27159055
[TBL] [Abstract][Full Text] [Related]
59. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
[TBL] [Abstract][Full Text] [Related]
60. Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study.
Gupta R; Islam S; Mony P; Kutty VR; Mohan V; Kumar R; Thakur JS; Shankar VK; Mohan D; Vijayakumar K; Rahman O; Yusuf R; Iqbal R; Shahid M; Mohan I; Rangarajan S; Teo KK; Yusuf S
Eur J Prev Cardiol; 2015 Oct; 22(10):1261-71. PubMed ID: 24942224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
